Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Asset Writedowns and Impairment (2021 - 2024)

Historic Asset Writedowns and Impairment for Lyell Immunopharma (LYEL) over the last 4 years, with Q2 2025 value amounting to $1.4 million.

  • Lyell Immunopharma's Asset Writedowns and Impairment changed N/A to $1.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was $52.7 million, marking a year-over-year change of. This contributed to the annual value of $51.3 million for FY2024, which is N/A changed from last year.
  • As of Q2 2025, Lyell Immunopharma's Asset Writedowns and Impairment stood at $1.4 million.
  • Lyell Immunopharma's 5-year Asset Writedowns and Impairment high stood at $51.3 million for Q4 2024, and its period low was -$5.0 million during Q4 2022.
  • Moreover, its 4-year median value for Asset Writedowns and Impairment was $5.0 million (2022), whereas its average is $17.8 million.
  • The largest annual percentage gain for Lyell Immunopharma's Asset Writedowns and Impairment in the last 5 years was 11371.86% (2022), contrasted with its biggest fall of 11371.86% (2022).
  • Over the past 4 years, Lyell Immunopharma's Asset Writedowns and Impairment (Quarter) stood at $36.4 million in 2021, then tumbled by 113.72% to -$5.0 million in 2022, then skyrocketed by 1126.0% to $51.3 million in 2024, then crashed by 97.19% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q2 2025, $51.3 million for Q4 2024, and -$5.0 million during Q4 2022.